To view this email as a web page, click
here.
|
Advertisement |
_1835612.jpg) |
|
|
|
|
|
As reported in the Journal of Clinical Oncology by McDermott et al, findings in a cohort of the phase II KEYNOTE-427 study showed that pembrolizumab monotherapy produced durable responses as first-line treatment for advanced non–clear cell renal cell carcinoma.
ADVERTISEMENT
|
Every year, significant amounts of drugs left over and unused from single-dose vials are discarded, but because of the way drugs are priced and paid for in the United States, the cost of the discarded amount cannot be recouped, according to a new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine. As many of these drugs are among the most expensive drugs on the market, including those for treating cancer, macular degeneration, and rheumatoid arthritis, the report highlighted several opportunities to reduce inefficiencies that could lead to a reduction in discarded drugs.
|
|
We're continuing our coverage of results presented at the 2021 Genitourinary Cancers Symposium, focusing on research findings in renal cell carcinoma and bladder cancer.
|
Advertisement
|
|
|
NEWSREELS FROM THE 2021 Genitourinary Cancers Symposium |
|
|
|
|
TRENDING IN BREAST CANCER |
|
|
In a study of germline genetic testing in women diagnosed with breast or ovarian cancer reported in the Journal of Clinical Oncology, Allison W. Kurian, MD, MSc, and colleagues found that undertesting persists in patients with ovarian cancer, and that most pathogenic variants are found in 20 breast cancer– or ovarian cancer–associated genes, with an increase in testing for additional genes being associated with increased identification of variants of uncertain significance.
As reported in the Journal of Clinical Oncology by Martine Piccart, MD, PhD, and colleagues, the preplanned second interim analysis of overall survival in the phase III APHINITY trial showed no significant benefit of the addition of adjuvant pertuzumab to chemotherapy plus trastuzumab after a median follow-up of 6 years in patients with early HER2-positive breast cancer. The invasive disease–free survival benefit observed with pertuzumab at the previously reported primary analysis persisted after long-term follow-up.
In a phase I trial reported in the Journal of Clinical Oncology, Aditya Bardia, MD, MPH, and colleagues identified activity of the oral selective estrogen receptor (ER) degrader elacestrant in postmenopausal women with heavily pretreated ER-positive, HER2-negative breast cancer, including those with the ER alpha gene (ESR1) mutation.
Breast cancer death rates have stopped declining for women in the United States younger than age 40, ending a trend that existed from 1987 to 2010, according to a report published by Hendrick et al in Radiology.
Research published by Martel et al in JNCCN—Journal of the National Comprehensive Cancer Network examined body mass index data for patients with HER2-positive early breast cancer—and found a 5% weight loss in patients over 2 years was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
|
|
|
|
|
|
|
|
|
|
Visit The ASCO Post Online at ASCOPost.com
Or
Visit and Follow Us
|
|
The ASCO Post™ is published by Harborside Press, LLC under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in The ASCO Post™ do not necessarily reflect those of Harborside Press, LLC, HSP News Service, LLC, or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Harborside Press, HSP News Service, LLC, and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions. |
|
|
|
|
INSERT_DYNAMIC_CONTENT_BLOCK_34492 |
|